NCT00331175View on ClinicalTrials.gov

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

December 31, 2006

Conditions
Obesity
Interventions
DRUG

Peptide YY3-36

Trial Locations (1)

Unknown

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00331175 - Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults | Biotech Hunter | Biotech Hunter